Sumitomo Mitsui DS Asset Management Company Ltd Increases Stock Position in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Sumitomo Mitsui DS Asset Management raised its stake in Vertex by 14.1% to 62,761 shares, valued at roughly $28.45 million at the end of the quarter.
• Vertex beat Q1 EPS ($4.47 vs. $4.24 est.) with revenue up 8.3% year‑over‑year and reiterated full‑year 2026 revenue guidance of about $13.0–$13.1 billion; analysts remain largely positive with a consensus price target of $554.83.
• Insider selling has been notable recently — roughly 81,853 shares (~$38.48 million) were sold over the last three months, leaving insiders with 0.20% ownership while institutional ownership stands at about 90.96%.

Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 14.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,761 shares of the pharmaceutical company's stock after purchasing an additional 7,767 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Vertex Pharmaceuticals were worth $28,453,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Colonial Trust Co SC grew its holdings in Vertex Pharmaceuticals by 118.8% during the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company's stock worth $27,000 after acquiring an additional 38 shares during the period. Eagle Bay Advisors LLC acquired a new stake in Vertex Pharmaceuticals in the fourth quarter valued at $29,000. Ares Financial Consulting LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth $33,000. Financial Network Wealth Advisors LLC grew its stake in shares of Vertex Pharmaceuticals by 50.9% during the 3rd quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company's stock worth $34,000 after purchasing an additional 29 shares during the period. Finally, Archer Investment Corp grew its stake in shares of Vertex Pharmaceuticals by 89.7% during the 4th quarter. Archer Investment Corp now owns 74 shares of the pharmaceutical company's stock worth $34,000 after purchasing an additional 35 shares during the period. 90.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently commented on VRTX shares. Barclays reiterated an "overweight" rating on shares of Vertex Pharmaceuticals in a research note on Wednesday. Oppenheimer lifted their price target on shares of Vertex Pharmaceuticals from $540.00 to $600.00 and gave the company an "outperform" rating in a research report on Tuesday, March 10th. Sanford C. Bernstein decreased their price target on Vertex Pharmaceuticals from $577.00 to $572.00 and set an "outperform" rating on the stock in a research note on Tuesday. Morgan Stanley upped their price target on Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an "overweight" rating in a report on Tuesday. Finally, Royal Bank Of Canada raised their price objective on Vertex Pharmaceuticals from $541.00 to $543.00 and gave the company an "outperform" rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $554.83.

Vertex Pharmaceuticals Trading Down 1.3%

Shares of NASDAQ VRTX opened at $424.36 on Wednesday. The company's 50-day moving average price is $452.77 and its 200 day moving average price is $449.59. Vertex Pharmaceuticals Incorporated has a 52 week low of $362.50 and a 52 week high of $507.92. The stock has a market cap of $107.94 billion, a price-to-earnings ratio of 25.17, a PEG ratio of 1.87 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $4.24 by $0.23. The company had revenue of $2.99 billion during the quarter, compared to analysts' expectations of $2.99 billion. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 24.41%. The firm's quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.06 earnings per share. As a group, research analysts expect that Vertex Pharmaceuticals Incorporated will post 16.81 earnings per share for the current year.

Insiders Place Their Bets

In other Vertex Pharmaceuticals news, EVP Joy Liu sold 1,104 shares of the company's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $425.02, for a total value of $469,222.08. Following the transaction, the executive vice president directly owned 20,729 shares in the company, valued at approximately $8,810,239.58. This represents a 5.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark E. Bunnage sold 620 shares of the firm's stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total transaction of $301,537.00. Following the sale, the executive vice president directly owned 7,284 shares in the company, valued at $3,542,573.40. This represents a 7.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 81,853 shares of company stock valued at $38,479,135. Insiders own 0.20% of the company's stock.

Key Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Q1 results beat on EPS and showed revenue growth driven by product sales; management highlighted broad portfolio strength and pipeline progress, supporting longer‑term growth thesis. Business Wire: Vertex Reports First Quarter 2026 Financial Results
• Positive Sentiment: Sales of new CF therapies and other recently launched products accelerated, contributing materially to product revenue growth and suggesting multiple near‑term commercial growth engines. Reuters: Vertex tops profit estimates as sales of new cystic fibrosis drug surge
• Neutral Sentiment: Vertex reiterated full‑year 2026 revenue guidance (~$13.0B–$13.1B), roughly in line with consensus — supportive for guidance stability but not a clear upside catalyst. Investor Slide Deck / Press Release (Q1 2026)
• Neutral Sentiment: Analysts revised models and price targets after the Q1 release — many maintained Outperform/Buy views but trimmed targets, reflecting mixed near‑term readings despite constructive longer‑term views. Benzinga: These Analysts Revise Their Forecasts On Vertex After Q1 Earnings
• Negative Sentiment: Insider selling was reported this week (EVP Joy Liu sold 1,104 shares; director Sangeeta Bhatia sold 318 shares). Trades were executed under 10b5‑1 plans, but active insider sales can weigh on sentiment. SEC Form 4 (Joy Liu) SEC Form 4 (Sangeeta Bhatia)
• Negative Sentiment: Shares dipped after the mixed report (EPS/revenue beats but some metrics and commentary left investors cautious), prompting near‑term profit‑taking and PT trims. Yahoo Finance: Vertex Dips On Mixed First‑Quarter Report

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.